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Abstract 
Background: rheumatoid arthritis (RA) is associated with loss of overall functionality of the locomotion system and it is 
connected with substantial economic losses. 
Objective: to describe the clinical characteristics and healthcare resource utilization characteristics and to analyze the 
correlations in a cross-sectional sample of 206 patients in Romania. 
Method: RA cases have been enrolled from southern and western part of the country, covering a surface of 23 counties. 
Results: particularly in the literature data, Romanian RA patients become work disabled at 5.65 ± 5.99 years old after the 
diagnosis. At cohort level, retirement in the first year after RA diagnosis is of 22.9%. From those, 13% were treated with biologic 
DMARDs; those on non-biologic DMARDs were 28.6%. In oral therapy group the most prescribed drug is lefunomide (61.2%). RA 
has an important impact on pain, function and utility, influenced by social factors. Patients’ follow up is often based on hospitalization. 
Conclusion: currently, when the clinician may choose for one certain therapy or another, the social influence is still 
overwhelming at all the evaluation levels in RA patients, as well as at economic impact. 
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Background 
At the beginning of the third millennium, starting with 
getting thoroughly into the molecular mechanisms 
responsible for the synovitis initiation in rheumatoid 
arthritis (RA), medical research has reached new therapy 
forms, through the biological agents. After the non-
biologic DMARDs (disease modifying antirheumatic 
drugs) era, the introduction of biological agents in the 
current medical practice has revolutionized the 
Rheumatology field. Recently, the RA evolution was 
described as a “potentially reversible/treatable physical 
disability” [1]. Parallel with this new therapy introduction, 
many clinical studies have shown its evidence based on 
short term and long term efficacy, as well as tolerability 
[5]. 
Treatment with biologic DMARDs is expensive. 
However, the better reduction of disease activity and 
effect on the retirement of a long-term physical function 
might be cost-saving to the community, because disease 
improvement might lead to the improvement of the quality 
of life but also to improved utilization of health resources 
(such as hospitalizations) and reduced sick leaving and 
work retirements. In International cost-utility analyses, it 
has already been shown that the extra costs to achieve 
the extra benefits are acceptable with cost-utility ratios 
falling between 50,000 -60,000 USD/ 1 QALY [5]. Is this 
acceptable in Romania? As long as these kinds of studies 
have not been performed in our country, the question still 
needs an answer. However, these studies were 
performed in Europe and North-America and cost-
effectiveness analyses cannot simply be transferred to 
other countries which have a different healthcare and cost 
system. In developing countries, along with Romania, the 
society has not enough power to entirely cover the 
payment mechanisms for all the patients who would 
theoretically have indication for biologics. As a 
consequence, a centralized settlement program was 
developed, according to a nationally validated protocol. 
Based on the parameters assessment, the access to Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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biologics is then decided.  
Considering these actualities how does the RA 
population in Romania looks like? What are the 
rheumatologists prescribing? What is the prescription 
trend and which are the factors that influence physicians 
to choose between the treatment options? Costs, 
benefits? What is the report between the therapy forms? 
These are only a few questions which need answers in 
order to expand the RA picture to other geographical, 
social and economical areas. These data might be the 
start for formal cost-effectiveness analyses. 
Rheumatoid arthritis: an up to date 
Rheumatoid arthritis (RA) is a systemic chronic 
inflammatory disease, with fluctuant evolution and 
unpredictable prognosis [8]; it leads to severe decline in 
functional status and quality of life and increases 
morbidity and mortality [7].  
RA induces considerable socio-economic effects [2, 
10-13]. It is known that after ten years of disease 
evolution, roughly half of the patients are work disabled; 
this brings the loss of productivity in the foreground of the 
RA economic impact [2, 9, 10, 14, 15]. 
The major therapeutically goal in RA is to interfere 
with the disease pathogenic paths. Stopping the joint 
destruction process would maintain the quality of life, 
through the prevention of physical disability and 
premature death. 
Pharmacological treatment represents the main 
option. The group of non-biologic remission agents,  
 
generically called DMARDs, consists of: methotrexate 
(MTX), sulphasalasine (SSZ), leflunomide (LFL), gold 
salts, hydroxiclorochine, D-penicillamine, 
cyclophosfamide, azathioprine, cyclosporine A. MTX is 
currently the most used remissive agent, being 
therapeutically considered the “gold – standard” [3]. 
The biologics introduction opened new perspectives 
at a pathogenically level (confirming the implications of 
the immunity elements) and at a clinical practice level, 
offering the alternative of the remission induction for non 
responders to non-biologic DMARDs.  
In Romania, the biological therapy uses anti TNF-α 
(alpha tumor necrosis factor) monoclonal antibody 
(Infliximab) and soluble receptors for TNF-α (Etanercept, 
Adalimumab) and anti CD20 antibodies (from B 
lymphocytes surface) (Rituximab). Chronologically, the 
first one introduced, having RA as indication was 
Infliximab, in 2000, followed by Etanercept, during 2004 
(indicated in juvenile idiopathic arthritis and starting with 
2005 in adult RA as well); during 2005 Adalimumab was 
also introduced. The latest biologic agent adopted in our 
country for clinical use is Rituximab, in 2008. 
From the National Health Insurance House database, in 
The National Committee for the Biological Therapy Approval 
for RA Patients, during the first trimester of 2006, a number 
of 1074 patients were on biologics, in the fourth trimester of 
2007 the total reaching 1500 patients, and in the same 
trimester of 2008 the total number of patients was 2143 
(Table 1).
 
 
Rheumatoid arthritis on biological therapy in Romania 
  Total  Infliximab  Etanercept  Adalimumab  Rituximab 
Trimester 1 – Year  2006  1074  954  117  3   
Trimester 4 – Year  2007  1500  840  455  205   
Trimester 4 –  Year  2008  2143  655  902  396  190 
Table 1. Rheumatoid arthritis on biological therapy in Romania 
 
European Health Systems 
Health systems are constantly changing. There are 
three main healthcare systems in Europe: “The National 
Healthcare System”, “The Social Health Insurances 
System” – Bismark and “The Centralized Healthcare 
System” – Semashko. The major differences between 
these are responsible for the consequences of medical 
practice. 
NHS was at first introduced in England but nowadays 
it can be also found in Denmark, Italy, Finland, Ireland, 
Norway, Sweden, Greece, Portugal and Spain. The 
system is financed through general taxes, in controlled by 
the government and has both a state budget and a private 
sector. All citizens have free access to the system, the 
coverage is general and the state authorities manage the 
system. In certain cases, the patients pay a part of the 
cost for some medical services. Its major disadvantage 
consists of long waiting lists for certain medical services 
and a high level of bureaucracy [6]. 
The Social Health Insurances System is the most 
used one and it is based on compiling the main elements 
of the social and medical insurances. This system 
operates in Germany, Austria, Belgium, Switzerland, 
France, Luxembourg and Netherlands. Even if the system 
offers a broad coverage, a certain part of the population 
remains outside the coverage area of the medical 
services. The system financing is based on the 
compulsory contributions of the employers and 
employees [6]. 
N.B.The numbers included as switches, as cases over 18 years old, who passed from pediatric department to adults one. Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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The Centralized Healthcare System, introduced in 
Russia was typical for the Central and Eastern European 
countries, which are now going through a transition 
process to the market economy. The state had full control 
over the production factors and health facilities and 
services. The doctors were state clerks and there was no 
private sector. The medical assistance was free for 
everyone employed oversized personnel and hospitals; it 
had no competition and it lacked performance [6]. 
Just like other former socialist countries, Romania 
organized the national healthcare system according to 
Semashko Russian model, based on free access to 
medical services for every citizen. Despite the fact that 
after the communism fell and reforms in healthcare 
system tried to get it closer to the German model, our 
system still fights with true weaknesses: little health 
expenditure as percentage in the GDP/capita (the current 
allocation is of only 3.2%, compared to the necessary of 
8% from GDP); centralized allocation of resources; 
overrated hospital services; lack of professional 
medical equipment and drugs; inequity in medical 
services delivery across the regions of the country [6]. 
Given this picture with ambiguous borders, what is really 
happening with RA patients who go beyond non-biologic 
DMARDs therapy phase being labeled as non- responsive? 
Paper objective 
Having designed an observational cross sectional 
cohort study of cost-effectiveness of the biological 
treatment compared to classical DMARDs, with a follow 
up period of 12 months, in this paper we proposed to 
describe the clinical characteristics and healthcare 
resource utilization characteristics and to analyze the 
correlations between a cross-sectional sample of 206 RA 
patients, at baseline (December 2007).  
Patients and methods 
The lack of a National RA Register, as well as a 
National RA Database has imposed a different sample 
enrollment method. We used two sources. Some of the 
cases are represented by patients from the Internal 
Medicine and Rheumatology Department of “Dr. Ion 
Cantacuzino” Hospital in Bucharest, during the year 2007. 
They have been drawn out chronologically, according to 
their time presentation, from the hospital electronic 
database. Inclusion criteria consisted of RA diagnosis and 
exclusion criteria, the presence of any malignancy. 
Through the collaboration with other rheumatologists 
within the country, other cases have been enrolled from 
the ambulatory care, in order to cover a larger territorial 
area: randomly, from their patients’ lists, based on the 
same inclusion and exclusion criteria. The RA diagnosis 
was established by each specialist (rheumatologist) for 
each patient apart.  
The patients – initially 480, recorded with names and 
addresses – were invited, through a post consent letter, to 
attend a scientific research. Three series of self report 
interviews were collected by post mail (at our address, 
written on the enclosed stamped envelope). The collected 
interval time was of six months, as following: 0 – 6 – 12 
months. The first interview was conducted during 
November – December 2007, the second one during May 
– June 2008 and the last one during November – 
December 2008. Following the first approach, from the 
initially 480 cases, we collected 206 responders’ 
envelopes (response rate being roughly 50%). These 
cases were considered eligible for the study; the second 
and third mail approach was conducted only for these last 
patients.  
Each serial evaluation consisted of three different 
questionnaires: an original one, Health Assessment 
Questionnaire (HAQ) Disability and Discomfort Scales – 
simple translation, not being validated in our country yet –
and EUROQOL EQ-5D, Romanian version (having the 
original authors’ consent for using it).  
The collected data (all self reports) were distributed 
on the following interest categories:  
(a) demographic (date of birth, age, sex, ethnic origin, 
marital status, environment of habitat, level of training, 
average income per month, professional status); 
(b) co-morbidities: the categories of patients with high 
blood pressure (HBP), diabetes mellitus (DM), chronic 
hepatitis (CH), coronary heart disease (CHD), gastro-
duodenal ulcer (GDU) - indicating episodes of digestive 
bleeding, renal failure (RF), asthma (A), osteoporosis 
(OP), osteoarthritis (OA), thyroid gland disease (T) and 
others have been noted together with arthroplasty 
procedures and other surgical interventions; 
(c) concerning the major disease (RA):  
- General features: diagnosis year, current treatment 
and its starting time, associated medication 
(corticotherapy /non steroidal anti-inflammatory drugs – 
NSAIDs). 
-  Functional characteristics: HAQ score, self 
reporting of pain intensity, disease activity and fatigue on 
a visual analogue scale of 100 mm (marked only at 
extremes), number of disabled days for usual activities, 
number of persons involved in home aid to its frequency. 
- Quality of life characteristics: utility (EQ-5D) and 
EQ-domains components (RA impact on mobility, self 
care, usual activities, pain/discomfort, anxiety/ 
depression), self reporting of the health quality on a visual 
analogue scale of 100 mm (feeling thermometer), marked 
each millimeter. 
-  Features of the economic impact with a time 
frame of 6 months: the number of sick leave days and 
hospitalization days, frequency for sick leave and 
hospitalizations, number of medical visits to the primary 
care and to rheumatologist, medical system appeals 
(regardless of the specialty), laboratory checks, number of 
X-rays, and CT/MRI examination, reporting on 
rehabilitation frequency, the patient’s monthly contribution 
(own pocket expenses) to the treatment. Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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Data analyses 
Geographically, the sample (n = 206) covers 23 
counties, from the Southern and Western part of the 
country (Fig. 1). The large territorial distribution of the 
cases as well as the normality statistical sample (Fig. 2), 
determined us to estimate that the sample is 
representative of the entire population suffering of RA, in 
our country.   
The data have been analyzed in the program SPSS 
10; we used ANOVA, two independent samples T test – 
for the continuous variables, Chi-Square, Kruskall Wallis 
and Man Whitney tests– for non-continuous variables, 
bivariate correlations (Pearson, Spearman coefficients). 
The sample has been subdivided according to the 
therapy, as it follows: group treated with oral agents  
 
(non-biologic DMARDs monotherapy and combinations = 
Group A) and biological agents group (biologic DMARDs 
= Group B). Seven cases have been excluded from the 
review: five without remission therapy (the size of the 
subgroup being too small to be analyzed compared to the 
other), and two other cases that have not responded to 
questions regarding the medication and could not be 
allotted to any group.  
Results, discussions, conclusions 
Sample and subgroups features, spread over the 
study categories at inclusion are summarized in Tables 2, 
3, 4, 5, 6, and 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic  Sample 
n = 206 
Group Aa 
n = 129 
Group Bb 
n = 70 
p value 
Group A versus B 
Age at inclusion (years)  54.90 ± 12.67  56.76 ± 12,25  51,84 ± 11,82  0,007* 
Women   86,4%  88,4%  84,3%  NS 
Urban   66%  64,3%  67,1%  NS 
Married   75,7%  79,8%  71,4%  NS 
Ethnicity (Romanian)  93,7%  93%  95,7%  NS 
Work active 
Retired  
Unemployed  
29,1% 
69,4% 
1,5% 
29,5% 
69% 
1,6% 
30% 
70% 
- 
NS 
NS 
NS 
Not school education 
Primary education level 
Medium education level 
Superior education level 
1% 
48,5% 
36,9% 
13,6% 
1,6% 
49,6% 
37,2% 
11,6% 
- 
48,6% 
34,3% 
17,1% 
NS 
NS 
NS 
NS 
Monthly income 
< 500 lei 
500 -1000 lei 
1000 – 1500 lei 
> 1500 lei 
 
61% 
29,3% 
7,8% 
2% 
 
60,5% 
31% 
7% 
1,6% 
 
62,9% 
25,7% 
10% 
1,4% 
 
NS 
NS 
NS 
NS 
Fig. 1. Cohort territorial distribution  Fig. 2. P-P plot for age (n=206) 
Results are given in average± DS for continuous variables and in percentages for non-continuous variables; a + b = 199 (7 
cases have been excluded after splitting the sample into therapeutic groups); group A= non-biologic DMARDs; group B= 
biologic DMARDs; * Level of significance alpha: p<0,05; NS=non statistically significant  
Table 2. Demographic characteristics Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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Although the patient’s age in group B is significantly 
lower (Table 2), this difference is not the notable one in 
the working activity status and income. It figures a RA 
population with an average age of 54.90 ± 12.67 years 
old, which is theoretically part of the working active 
category. Practically, however, two thirds are retired, most 
cases have low monthly income (<1000 lei/month, to 
90.3%),  
 
and approximately half of them have completed only 
primary education (it seems we are dealing with a RA 
population of young people, poor and elementary 
trained?). In this framework, between the level of 
education and the monthly income, there is a 
homogeneous significant positive correlation in both 
groups (ρs = 0.645, p ≤ 0.01). These issues outline the 
social conditions in the demographic characteristics 
background. 
 
 
 
 
Characteristic  Sample 
n = 206 
Group Aa 
n = 129 
Group Bb 
n = 70 
p value 
Group A versus B 
Total no. comorbidities 
0 
1 
2 
3 
4 
5 
6 
7 
 
16,7% 
18,1% 
19,1% 
20,6% 
12,3% 
6,4% 
4,4% 
2,5% 
 
15,5% 
19,4% 
20,9% 
17,1% 
12,4% 
6,2% 
6,2% 
2,3% 
 
17,6% 
16,2% 
17,6% 
23,5% 
13,2% 
7,4% 
1,5% 
2,9% 
NS 
 
 
Groups comorbidities 
 
High blood pressure  49,5%  53,5%  42,6%  NS 
Osteoporosis  40,2%  40,3%  39,7%  NS 
Coronary heart disease  29,9%  32,6%  23,5%  NS 
Osteoarthritis   23%%  24%  22,1%  NS 
Gastro-duodenal ulcer  21,1%  18,6%  27,9%  NS 
Diabetes mellitus  16,2%  17,1%  16,2%  NS 
Thyroid gland disease  15,7%  14,7%  17,6%  NS 
Renal failure  9,8%  9,3%  11,8%  NS 
Asthma  7,4%  7,8%  7,4%  NS 
Chronic hepatitis  3,9%  3,9%  4,4%  NS 
Others   26%  27,9%  22,1%  NS 
   
Digestive bleeding  3,5%  4,8%  1,4%  NS 
 
Surgery  
 
Arthroplasty   3,9%  1,6%  7,1%  0,04* 
Other surgical procedure 
(out of the RA context) 
9,8%  9,3%  11,4%  NS 
 
 
Morbidity is significantly associated with PR 
(Table 3). Over half of the patients (57.3%) had 
associated three diseases with PR, in terms of population 
with an average age of 54.90 ± 12.67 years old. Between 
them, the first three places are occupied by high blood 
pressure, osteoporosis and coronary heart disease; as 
already confirmed, cardiovascular diseases increase the 
mortality rate, independently. It also remarks the 
significantly higher arthroplasty rate in B (7.1%, compared 
to 1.6%; p<0.05): it refers to a history of more severe 
diseases for the current biologics cases. 
 
N.B. Results are given in percentages for non-continuous variables; a + b = 199 (7 cases have been excluded after splitting the 
sample into therapeutic groups); group A= non-biologic DMARDs; group B= biologic DMARDs; * Level of significance alpha: 
p<0,05; NS=non statistically significant  
Table 3. Associated RA morbidities: characteristics Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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Characteristic  Sample 
n = 206 
Group Aa 
n = 129 
Group Bb 
n = 70 
p value 
Group A versus B 
Disease duration starting diagnosis (ys)  9,40 ± 8,87  8,24 ± 8,93  11,32 ± 8,30  0,01* 
 
Treatment: therapeutically groups 
 
       
No remissive treatment  2,5%  -  -  NA 
Non-biologic DMARDs monotherapy  47,1%  74,4%  -  NA 
Non-biologic DMARDs combinations  16,2%  25,6%  -  NA 
Biologic DMARDs plus MTX  25,5%  -  74,3%  NA 
Biologic DMARDs without MTX  8,8%  -  25,7%  NA 
 
Treatment: DMARD preparatesc 
 
       
MTX  48,6%  36,4%  74,3%  NA 
SSZ  19,6%  27,1%  7,1%  NA 
LFL  42,2%  61,2%  10%  NA 
 
Treatment: biologic agents 
 
       
Infliximab  65,7%  -  65,7%  NA 
Etanercept  20%  -  20%  NA 
Adalimumab  14,3%  -  14,3%  NA 
Mean duration of current treatment (ys)  2,70 ± 2,64  2,71 ± 2,86  2,71 ± 2,19  NS 
 
Anti-inflammatory drugs 
 
       
NSAIDs  89,2%  91,4%  88,2%  NS 
Monthly NSAIDs intake 
None  
< 10 days 
10 – 20 days 
> 20 days 
Daily  
 
10,8% 
17% 
25,3% 
11,3% 
35,6% 
 
9,1% 
19,0% 
26,4% 
8,3% 
37,2% 
 
11,9% 
14,9% 
23,9% 
16,4% 
32,8% 
 
NS 
NS 
NS 
NS 
NS 
Corticotherapy  39%  37,8%  39,7%  NS 
 
 
Average disease duration is of 9.40 ± 8.87 years old, 
with a significant difference between groups in favor of 
biologics (11.32 ± 8.30 years old). In other words, 
biological agents predominate in older forms of the 
disease at a younger category of patients. If in group A, 
RA age increases linearly with age (r = 0.233, p ≤ 0.01) in 
group B these factors are independent, supporting a 
broader distribution of the cases on the age axis. 
On figures (Table 4), two thirds of patients are 
following non-biologic DMARDs (¾ monotherapy, ¼ 
combinations), and one third, biological agents. 
Interesting is that assessing the entire sample, the most 
prescribed DMARD seems to be MTX (48.6%) – including 
here MTX prescriptions associated with biologics – while 
N.B. Results are given in average± DS for continuous variables and in percentages for non-continuous variables; a + b = 199 (7 
cases have been excluded after splitting the sample into therapeutic groups);  
c percentages include monotherapy and combinations; group A= non-biologic DMARDs; group B= biologic DMARDs; * Level of 
significance alpha: p<0,05; NS=non statistically significant; NA = not applicable; NSAIDs =non steroidal anti-inflammatory drugs; 
MTX=methotrexate; SSZ= sulphasalazine; LFL = leflunomide. 
Table 4. General characteristics of rheumatoid arthritis Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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looking only in group A (non-biologic DMARDs), first place 
is occupied by LFL (61.2%). The explanation relies on two 
aspects: on the one hand, surprising RA population at 
approximately 10 years from the disease evolution, when 
most patients are beyond stage MTX, either through 
inefficiency (secondary resistance) or by cumulative dose 
over time; on the other hand, the influence role of various 
pharmaceutical companies in prescribing a certain drug 
should not be missed. What is interesting about the 
analyzed population is that other DMARDs preparations 
were not declared, which draws attention to a phase of 
decline in using a medication formerly overused (gold 
salts, hydroxycloroquine etc.), as well as to a selective 
promotion of products from pharmaceutical companies. In 
the biologics group, the "oldest" drug is placed on top of 
the most prescribed one: Infliximab (65.7%). This feature 
follows the national wide distribution of TNF blockers 
agents in “The National Committee for the Biological 
Therapy Approval” (Table 1), where Infiliximab was the 
most frequently biologic at the end of 2007. We conclude 
that these figures reflect a stage of plateau in the dynamic 
of the described parameters, as the average duration of 
the reported treatment is of 2.70 ± 2.64 years old. 
AINS consumption is high (89%), without differences 
between groups. Looking at the figures, over ⅓ of the 
cases require daily NSAIDs (35.6%). Considering 
correlation with age and disease duration, NSAIDs intake 
increased with RA age only in group A (ρs = 0.212; p≤ 
0.05). Supporting these data with associated pathology, 
the risk of adverse events, even fatal (by major cardio-
vascular disorders) is amplified. 
Corticotherapy is part of the treatment in 39% of the 
cases. Looking at sample level, the relationship 
corticotherapy -  HAQ disability categories (Fig. 3), 
cortisone therapy is missing in 73% of the cases for HAQ 
categories <1.6; starting with HAQ scores> 1.6 
corticotherapy is present at 59% (p ≤0.01). The ratios are 
different in subgroups. Group A describes a similar curve, 
except for the report reversal point starting with HAQ 
values of > 2.1. On the contrary, in group B cortisone 
therapy is present in 81% of the cases belonging to the 
HAQ category: 1.6-2.1; in all other intervals, the majority 
of the patients do not require cortisone therapy, even for 
HAQ values <1.6, as for those > 2.1 (75 % and 58% 
patients, respectively), p ≤ 0.01. 
Surprisingly, group B described a positive correlation 
(ρs = 0.247, p ≤ 0.05) between corticotherapy and age. It 
clearly appears that the oldest patients belong mostly to 
HAQ interval 1.1 – 2.1 (meaning moderate and advanced 
disability), the same area recorded a peak in cortisone 
therapy, as well.  
At least two conclusions can be detached: in oral 
therapy group, “RA end stage" of irreversible disability 
(27.2%) is frequently cortisone dependent; in this group, 
corticotherapy describes a linear growth in the degree of 
disability, in order to maintain a minimum functionality of 
the locomotion system. On the contrary, in biologics group 
cortisone prescription follows the disability intervals 
potentially reversible (HAQ 1.1 – 2.1), where the case 
density is also the highest (51.5%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is working activity status related to the consumption 
of NSAIDs and cortisone? In group B, the retired cases 
correlate positively with corticotherapy (ρs = 0.260, p ≤ 
0.05) and with NSAIDs intake (ρs = 0.265, p ≤ 0.05), 
while the correlation is negative for the active professional 
cases. This reflects the former severity of the disease in 
group B: more severe disease (HAQ represents partly the 
cumulative disease activity – damage over time) reduces 
ability to work and makes it more likely to receive steroids 
and/or NSAIDs. Considering that groups have not 
significant differences concerning the active professional 
proportion, it seems that in the oral therapy group, these 
factors are independent. It could also reflect a former less 
severity of the disease in group A. 
In functional terms (Table 5) the average HAQ score 
at baseline was of 1.29 ± 0.80. If we look to HAQ 
categories, household activities recorded the most severe 
score (36.9% of cases), followed by hygiene (17.9%). 
Considering 6 categories of severity, corresponding 
to a certain range of HAQ score, we mention: in group A, 
27.2% of cases are severely and very severely disabled, 
compared to 15.7% in group B (p ≤ 0.05). Advanced and 
moderate disability is observed in 51.5% of cases 
representing group B, compared to 27.1% of group A (p ≤ 
0.05) (Fig. 4). In other words, RA terminal phases (end-
stage) which have less therapeutically benefits in 
functional terms are mostly treated with classical agents, 
while the potentially reversible stages of RA disability can 
be found especially in the group receiving a more 
expensive therapy. In a society with limited health 
resources, this "selective affiliation" of cases is 
predictable, considering as a therapeutic target also the 
socio-economic reinsertion of patients. 
Age is a factor that increases the degree of disability 
appreciated by HAQ (r = 0.417, p ≤ 0.01); on the contrary, 
Categorii HAQ
> 2.6 2.1-2.6 1.6-2.1 1.1-1.6 0.6-1.1 < 0.6
%
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Fig. 3. Corticotherapy in relation with HAQ categories Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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less obvious correlation of disability in relation to disease 
duration (r = 0.251, p ≤ 0.05). In the same polarity, we 
mention HAQ influence on the retired status (ρs = 0.318, 
p ≤ 0.01). 
Using of self-quantitative VAS scale showed 
unexpected high scores for pain (mean 54.45 ± 24.23), 
disease activity (mean 55.17 ± 23.12) and fatigue (57.49 
± 24.87). Age is an inflexible characteristic, but its 
influence on self reporting assessments is confirmed by 
the positive correlation with the mentioned variables (r = 
0.219, 0.259, 0.272, p ≤ 0.01). 
Although approximately ¼ of the cohort (22.8%) 
belongs to a functional irreversible RA phase, needed 
assistance in everyday life overcomes the expected level: 
86.7% of patients require household help and 58.3% of 
them frequently report and permanently help. One single 
person is involved in house hold help for most of the  
 
cases (68.8%), 41.7% of patients call for auxiliary objects 
and 35% for aid devices, mostly for the category of usual 
daily activities (64.6%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic  Sample 
n = 206 
Group Aa 
n = 129 
Group Bb 
n = 70 
p value 
Group A versus B 
HAQ score  1,29 ± 0,80  1,27 ± 0,84  1,34 ± 0,72  NS 
Severity categories (HAQ score) 
  Least Disability:                  < 0,6 
Mild Disability:             0,6 – 1,1 
    Moderate Disability:     1,1 – 1,6  
               Advanced Disability:    1,6 – 2,1 
Severe Disability:         2,1 – 2,6  
Very severe Disability:       > 2,6   
 
21,4% 
19,9% 
19,4% 
16,5% 
14,1% 
8,7% 
 
24,8% 
20,9% 
14,7% 
12,4% 
16,3% 
10,9% 
 
14,3% 
18,6% 
28,6% 
22,9% 
10,0% 
5,7% 
0,02* 
 
Frequency of helping object  41,7%  39,5%  45,7%  NS 
Frequency of helping device  35%  32,6%  40%  NS 
Most severe HAQ score category 
Daily activities 
Hygiene  
Dressing and self-care 
 
36,9% 
17,9% 
10,7% 
 
39,2% 
20,6% 
9,8% 
 
34,4% 
14,8% 
11,5% 
NS 
HAQ helping categories 
Daily activities  
Grip  
Reach 
Hygiene 
 
64,6% 
47,6% 
39,8% 
25,7% 
 
62% 
48,8% 
40,3% 
22,5% 
 
68,6% 
45,7% 
40% 
30% 
NS 
Self reporting through VAS 
Pain 
Disease activity  
Fatigue  
 
54,45 ± 24,23 
55,17 ± 23,12 
57,49 ± 24,87 
 
54,94 ± 24,88 
56,30 ± 23,83 
58,50 ± 25,91 
 
54,22 ± 22,83 
53,46 ± 21,57 
56,68 ± 22,59 
NS 
Monthly lost days for usual activities  9,64 ± 9,06  9,12 ± 9,32  10,43 ± 8,55  NS 
Frequency of household help  
Rare 
Frequent 
Permanent 
86,7% 
28,4% 
32,5% 
25,8% 
85,7% 
28,6% 
29,4% 
27,7% 
88,4% 
29,0% 
36,2% 
23,2% 
NS 
 
Persons needed for household help   
     1 
2 
3 
 
68,8% 
8,5% 
2% 
 
66,1% 
8,1% 
1,6% 
 
73,9% 
10,1% 
2,9% 
NS 
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Fig. 4. HAQ categories according to therapy groups 
N.B. Results are given in average± DS for continuous variables and in percentages for non-continuous variables; a + b = 199 (7 
cases have been excluded after splitting the sample into therapeutic groups); group A= non biologic DMARDs; group B= biologic 
DMARDs; * Level of significance alpha: p<0,05; NS=non statistically significant. 
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Overall functional impact in daily life is materialized in 
about ten days lost every month because of the inability of 
performing household tasks (average: 9.64 ± 9.06 days). 
There is an important and relatively homogeneous 
positive correlation between lost days and the self 
reporting level for pain, fatigue and disease activity (r = 
0.650, p ≤ 0.01) in both groups. 
The category of working active cases has a certain 
degree of independence at home. Both groups reveal a 
negative correlation of these cases with lost days for 
usual activities (ρs = -0.255 and -0.351, p ≤ 0.01), while in 
group A the help frequency is bigger (ρs =- 0.307, p ≤ 
0.01); pensioners group correlation is positive (meaning 
an increase in non-medical direct costs). 
Utility (Table 6), appreciated on a scale from 0 to 1,  
 
where 1 corresponds to perfect quality and 0 to death, is 
placed for the whole sample to an average of 0.417 ± 
0.337. Between groups, there is a difference in favor of 
biologics (0.382 ± 0.347 and 0.452 ± 0.317, p = 0.1), but 
both figures belong to a low level. The most frequently 
reported score was of 0.516 and it was found in one third 
of cases. It is interesting that the proportion of those who 
reported moderate and severe problems in the utility 
components stratify somehow the RA impact in patient 
daily life. Thus, 95.5% reported pain / discomfort, 83% 
have problems in mobility and usual activities, 74% in self 
care and 69% have anxiety / depression. 
The quality of health state assessed through VAS 
showed an average score of 47.39 ± 22.13, with a 
statistically significant difference between groups in favor 
of biologics (44.92 ± 22.34, and 51.36 ± 21, 23, p ≤ 0.05). 
 
 
 
 
 
Characteristic  Sample 
n = 206 
Group Aa 
n = 129 
Group Bb 
n = 70 
p value 
Group A versus B 
Utility - EQ5D   0,417 ± 0,337  0,382 ± 0,347  0,452 ± 0,317  0,1 
Most frequently reported utility values 
0,516 
0,587 
 
32,7% 
10,2% 
 
31,7% 
9,2% 
 
33,3% 
11,6% 
NS 
Utility components** 
Mobility 
Self care 
Usual activities 
Pain/Discomfort 
Anxiety/Depression 
 
83% 
73,9% 
83,4% 
95,5% 
69% 
 
84,6% 
73% 
83,6% 
98,4% 
71,9% 
 
82,9% 
75,7% 
84,3% 
92,9% 
65,2% 
 
NS 
NS 
NS 
0,03* 
NS 
EQ5D – VAS: quality of health state  47,39 ± 22.13  44,92 ± 22,34  51,36 ± 21,23  0,05* 
 
 
In both subgroups increased disability lowers the 
quality of health state and utility. (group A: ρs = - 0.618, -
0.665 (p ≤ 0.01); ρs group B = -0.707 - 0.552 (p ≤ 0.01). 
Given the social context of RA patient in Romania, 
we consider it appropriate to present the correlations of 
some social elements with quality of life components, 
independently of other factors directly related to RA: 
-  The increasing level of education is 
associated with health state quality and utility: r = 
0.377 and r = 0.380, where p ≤ 0.01. 
-  There is an association between the 
standard of living caused by a low monthly income 
and utility score, as well as quality of health state: r = 
0.323 and r = 0.364, where p ≤ 0.01. 
-  There is an association between the 
low monthly income and the severity of utility 
components: mobility (ρs = -0.186), self care (ρs =-
0.302), usual activities (ρs = - 0.304), pain/discomfort 
(ρs = -0.233), anxiety/depression (ρs = -0.216), 
where p ≤ 0.01. 
-  There is an association between 
inactivity (retired group) and the severity of utility 
components: ρs = 0.224; 0.250; 0.255; 0.167; 0.220, 
where p ≤ 0.01. 
In order to improve the RA impact at individual, social 
and economic level, some supporting and stimulating 
measures of any working activity, tailored according to the 
disease functionality are required.  
 Analyzing the effectiveness, strictly in terms of utility 
and quality of health state, the biologics class is clearly 
superior to classical therapy. Expanding to the level of 
economic impact characteristics, the differences between 
groups did not describe the same behavior (Table 7). 
Reported to the active professional subgroup, labor 
productivity was evaluated by sick leave and early 
retirement. 
Quantifying the absenteeism frequency, 20% of the 
patients reported sick leave in the last 6 months. There is 
however a significant difference in sick leave duration, in 
favor of group A (mean 3.58 ± 8.66 days, compared to 
0.43 ± 1.08 days in group B, p ≤ 0.05). The analysis of 
N.B. Results are given in average± DS for continuous variables and in percentages for non-continuous variables; ** 
Percentages represent frequency of problems (moderate and severe) in mentioned category; 
a + b = 199 (7 cases have been excluded after splitting the sample into therapeutic groups); group A= non biologic DMARDs; 
group B= biologic DMARDs; * Level of significance alpha: p<0,05; NS=non statistically significant. 
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correlation with the hospitalization duration revealed that 
the two features are independent. As a result, in DMARDs  
group longer sick leaves is not a consequence of 
hospitalization, but probably of outpatient visits in the 
primary care or rheumatologist, the only ones who can fix 
sick leave in ambulatory care. 
Labor productivity loss through early retirement  
reaches a threshold of 38.5% of cases (33.7% in group A  
and 46.9% in group B) at a median duration after RA 
diagnosis time of only 5.65 ± 5.99 years (also the 
comparable average between groups). What is interesting 
is that in the first year after RA diagnosis, 22.9% of the 
newly diagnosed patients are medically retired (28.6% 
belonging to group A and 13% to group B). Recall that 
literature sustains a loss of labor productivity through work 
incapacity of about 50% in the first 10 years after 
diagnosis [15]. 
 
 
 
 
 
 
Characteristic  Sample 
n = 206 
Group Aa 
n = 129 
Group Bb 
n = 70 
p value 
Group A versus B 
Sick leave /6 months c  20%  23,7%  14,3%  NS 
Days of sick leave / 6 months c  2,42 ±7,06  3,58 ±8,66  0,43 ± 1,08  0,03* 
hospitalizations / 6 months  52,4%  47,2%  67,1%  0,007* 
Days of hospitalization / 6 months  5,42 ±7,67  4,79 ± 7,21  6,82 ± 8,52  0,08 
Loss of labor productivity: RA pensioners d 
RA retirement after diagnosis time – years 
RA retirement in FIRST YEAR after diagnosis e 
38,5% 
5,65 ±5,99 
22,9% 
33,7% 
5,76 ± 6,81 
28,6% 
46,9% 
5,52 ± 5,33 
13% 
NS 
NS 
0,1 
Rheumatologist visits /6  months 
6 visits 
3 visits 
2 visits 
0 visits 
 
32,3% 
19,4% 
15,4% 
3% 
 
39,2% 
11,2% 
18,4% 
4,8% 
 
21,4% 
35,7% 
8,6% 
- 
0,000* 
Primary care visits (GP) / 6 months 
6 visits 
3 visits 
2 visits 
0 visits 
 
41,7% 
7,5% 
8,5% 
15,6% 
 
46% 
6,5% 
6,5% 
16,1% 
 
34,8% 
8,7% 
11,6% 
14,5% 
NS 
Medical system appeal  (global) / 3 months 
3 appeals 
2 appeals 
1 appeal 
0 appeals 
 
26,9% 
10,4% 
15,5% 
13,5% 
 
27,1% 
7,6% 
13,6% 
17,8% 
 
27,5% 
15,9% 
17,4% 
7,2% 
NS 
Specialty (regardless of rheumatology and GP) 
Cardiology 
Gynecology 
Endocrinology 
Diabetology 
Dermatology 
 
4,4% 
3,9% 
2,9% 
2,4% 
2,4% 
 
4,7% 
3,1% 
3,9% 
1,6% 
3,1% 
 
2,9% 
4,3% 
1,4% 
4,3% 
1,4% 
NS 
Lab tests sets 
3 sets 
2 sets 
1 set 
0 sets 
 
26,2% 
39,6% 
16,8% 
1% 
 
21,4% 
42,9% 
19,8% 
0,8% 
 
35,7% 
34,3% 
10% 
- 
0,004* 
Xrays number 
>3 Xays 
1 – 3 Xrays 
0 Xray 
 
9,4%% 
50,7% 
39,9% 
 
12,6% 
55,1% 
32,3% 
 
2,9% 
45,7% 
51,4% 
0,008* 
CT  
MRI 
0,5% 
0,5% 
0,8% 
0,8% 
- 
- 
NS 
Own pocket expenses/ monthly 
<50 lei 
50 – 100 lei 
< 100 lei 
 
34,7% 
39,8% 
25,5% 
 
38,5% 
36,1% 
25,4% 
 
26,5% 
45,6% 
27,9% 
NS 
 
Rehabilitation  10,8%  10,2%  11,4%  NS 
N.B. Results are given in average± DS for continuous variables and in percentages for non-continuous variables; a + b = 199 (7 
cases have been excluded after splitting the sample into therapeutic groups); c: n = 60 (working active subgroup); d: n = 143 
(retired subgroup); e: n = 55 (RA retired subgroup);  group A= non biologic DMARDs; group B= biologic DMARDs; * Level of 
significance alpha: p<0,05; NS=non statistically significant. 
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What caused the patients to be declared work 
disabled so early? No evident correlations (factors with 
independent behavior) were found between the disability 
degree (HAQ) and the time elapsed from the diagnosis 
moment to the RA retirement. On the contrary, there is a 
strong positive correlation (r = 0.758, p ≤ 0.01) between 
RA age and time elapsed from diagnosis until RA 
retirement. By adding age in this equation, no additional 
information result was found. From this perspective, RA 
age, not patient age, comes in the foreground of RA 
impact on labor productivity. 
However, figures show that a significant proportion of 
patients are declared work disabled at less than one year 
from the time of diagnosis. From this perspective, RA age 
losses the top position in final decision on work capacity. 
Considering also some social factors, we found 
interesting associations: 
-  reduction of monthly income is 
associated with time from RA diagnosis to ill 
retirement (r = 0.565, where p ≤ 0.01; 
-  the highest the education level is, the 
greater the tendency to remain active 
professionally results (significant positive 
correlation in both groups, but more expressed in 
group B: ρs = 0.466, p ≤ 0.01). 
In conclusion, it seems that in our country the social 
level of RA patients plays also a major role in the loss of 
work productivity. This socio-economic weakness 
supports a vicious circle: "small proportion of work active 
population - insufficient funds allocated in the health 
system - great selection and low accessibility of patients 
to more expensive therapies, even if with superior 
efficiency”. 
Regarding the follow up visits to the rheumatologist, 
⅓ of cases reported monthly visits, the differences being 
statistically significant between groups (39% - group A, 
compared with 21% - group B, p ≤ 0.01); 20% of cases 
are monitored at intervals of 2 months (11.2% group A, 
compared with 35.7% in group B, p ≤ 0.01). From the 
entire cohort perspective, the rhythm of monitoring visits 
has no correlation with the disability severity (HAQ). 
Given this aspect and also considering the economic 
implications of a medical check, a question arises: what 
induces the rhythm of follow up? Looking within groups on 
disability levels, patients with more severe disabilities are 
monitored on monthly basis; differences occur in cases of 
HAQ interval 0.6 - 2.1. Thus, in group A, most cases are 
monitored monthly; in group B dominate 2 months visits. 
In terms of the drug prescription, most of non-biologic 
DMARDs recipes belong to the primary care network. 
Thus, monthly rheumatology visits for the lower 
categories of disability could have two interpretations: on 
one hand, it could support the excess use of health care 
departments (inside and outside hospital), but on the 
other hand the patients could have better function 
because they come to the hospital more frequently. The 
study design implies 1 year of follow up, so the patient’s 
characteristics dynamic will support one of these two 
hypotheses (which will be reported, as well). In group B, 
two months follow up is probably related to the 
administration rhythm of infliximab. At this point, it seems 
that rheumatology monitoring rhythm is determined by the 
clinician.  
41.7% of cases appeal monthly the primary care 
network and 27% have monthly visits to other specialties; 
cardiology hold on the top.  
Regarding the lab tests monitoring, approximately ¼ 
cases are tested at 2 months interval, but with significant 
differences between groups: 35.7% in group B, compared 
to 21.4% in group A (p ≤ 0.01). The biologic patient is 
therefore more closely monitored biologically. These data 
reflect physician option. 
Radiological monitoring revealed that about ¼ of 
cases failed to X-ray control in the last 6 months, with 
significant differences between groups (32% group A, 
group B 51%, p ≤ 0.01), while ½ of cases had from 1 to 3 
radiographs. 
For 75% of cases, the monthly patient contribution to 
the treatment is less than 100 lei, with no significant 
differences between groups. This level of own pocket 
expenses represent 10% of the average monthly income, 
for 90% of the patients included. 
Concerning direct medical costs level, the economic 
impact reveals that hospitalizations rate (reported for half 
of the cases) is significantly higher in group B (67.1% 
versus 47.2%, p ≤ 0.01). Although no significant 
differences between groups as extent of hospitalizations 
(6.82 days and 4.79 days), it seems that with age 
increase, only patients treated with biological agents 
require more frequent hospitalizations and of longer 
duration (r = 0.529, p ≤ 0.01), amplifying direct costs, 
eventually. 
The frequency and duration of hospitalization is 
directly related to the degree of disability in group A (ρs = 
0.323, p ≤ 0.01), while in group B, it is valid for the 
duration of hospitalization, not for its frequency (ρs = 0, 
329; p ≤ 0.01). 
With respect to the superior hospitalization rate in 
group B, there is not a discrepancy without explanation. 
The reason lies in the large proportion of biologics 
patients treated with Infliximab, which is managed only 
through hospital admission.  
In conclusion, in our country, the rate of 
hospitalizations is not only a consequence of RA relapse 
episodes. The current health care system services still 
hospitalized based, associated to a particular social 
context, could increase direct medical costs in cases not 
related to compulsory hospitalization. The claim requires 
evidence in support of monetary unit, providing by data 
analysis which will be soon reported.  Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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